Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yuhong Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6333-8226; OpenAlex author ID A5064161818. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 9

  1. A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adeno… Co-author DOI 10.1038/s41392-025-02530-2↗
  2. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma… Co-author DOI 10.1038/s41392-024-01948-4↗
  3. Identification of Novel Tumor Pyroptosis-Related Antigens and Pyroptosis Subtypes for Developing mRNA Vaccines in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/biomedicines12040726↗
  4. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection ma… Co-author DOI 10.3389/fonc.2023.1109068↗
  5. Negative regulation between the expression levels of receptor for hyaluronic acid-mediated motility and hyaluronan leads to cell migration in pancreatic cancer. Co-author DOI 10.3892/ol.2020.12060↗
  6. Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. First author DOI 10.3389/fonc.2019.01543↗
  7. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Last author DOI 10.1093/jjco/hyy063↗
  8. Role of transgelin-2 in diabetes-associated pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.17519↗
  9. SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism. Co-author DOI 10.1007/s13277-015-3047-5↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xi Guo · 4 shared papers, 2018–2024 · strength 0.56
  2. Lili Wu · 4 shared papers, 2018–2023 · strength 0.43
  3. Yue Fan · 3 shared papers, 2018–2023 · strength 0.33
  4. Yaolin Xu · 2 shared papers, 2018–2023 · strength 0.24
  5. Dansong Wang · 2 shared papers, 2018–2023 · strength 0.24
  6. Wenchuan Wu · 2 shared papers, 2018–2023 · strength 0.24
  7. Jun Zhou · 1 shared paper, 2025 · strength 0.24
  8. Zhi-Hua Li · 1 shared paper, 2025 · strength 0.24
  9. Miaoyan Wei · 1 shared paper, 2025 · strength 0.24
  10. Lin Shen · 1 shared paper, 2025 · strength 0.24
  11. Ran Xue · 1 shared paper, 2025 · strength 0.24
  12. Xianjun Yu · 1 shared paper, 2025 · strength 0.24
  13. Qiaowei Lin · 1 shared paper, 2024 · strength 0.23
  14. Yefei Rong · 1 shared paper, 2024 · strength 0.23
  15. Wenhui Lou · 1 shared paper, 2023 · strength 0.17
  16. Chuntao Gao · 1 shared paper, 2024 · strength 0.15
  17. Jiuwei Cui · 1 shared paper, 2024 · strength 0.15
  18. Jun Yao · 1 shared paper, 2024 · strength 0.15
  19. Jufeng Wang · 1 shared paper, 2024 · strength 0.15
  20. Liwei Wang · 1 shared paper, 2024 · strength 0.15
  21. Zhihua Li · 1 shared paper, 2024 · strength 0.15
  22. Tao Xia · 1 shared paper, 2024 · strength 0.15
  23. Jiujie Cui · 1 shared paper, 2024 · strength 0.15
  24. Deliang Fu · 1 shared paper, 2024 · strength 0.15
  25. Shukui Qin · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.